This is a non-core endpoint: only basic statistics are computed.
Follow-up examination after treatment for malignant neoplasms
Z21_FOLLOW__EXAM_TREAT_MALIG_NEOPLASMS
No definition available.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
3726
Check minimum number of events None
3726
Include endpoints None
3726
Remove individuals based on genotype QC
3623
Z21_FOLLOW__EXAM_TREAT_MALIG_NEOPLASMS
Control definitions
Control exclude
Z21_PERSONS_ENCOUNTERI_HEALTH_SERVI_EXAM_INVES
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
Z[0-1]
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Follow-up examination after treatment for malignant neoplasms
based on the number of shared cases.
Broader endpoints:
- Persons encountering health services for examination and investigation
- Factors influencing health status and contact with health services
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3623 | 2030 | 1593 |
| Unadjusted prevalence (%) | 0.88 | 0.88 | 0.88 |
| Mean age at first event (years) | 63.94 | 60.16 | 68.75 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: Z21_FOLLOW__EXAM_TREAT_MALIG_NEOPLASMS – Follow-up examination after treatment for malignant neoplasms
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Follow-up examination after treatment for malignant neoplasms
↥Endpoint not on priority list, no data to show.